Abstract:OBJECTIVE:To identify the effect of postoperative adjuvant transarterial chemoembolization (TACE) on late recurrence of hepatocellular carcinoma (HCC) patients after radical resection. METHODS:From year 2001 to 2007, 2436 HCC patients underwent radical resection were retrospectively selected. Patients underwent resection only were classified into control group, while those received adjuvant TACE within 2 months after operation were classified into intervention group. Patients were further stratified into those with tumor5 cm and presenting low or high risk factors for recurrence. Patients with single tumor and without microscopic tumor thrombus were defined as low risk for recurrence; otherwise they were defined as high risk. The effect of adjuvant TACE on late (>2 years) recurrence was evaluated. RESULTS:Recurrence rates of tumor5 cm and presenting low, high risk factors for recurrence at 2-year after resection were 20.38%, 33.06%, 30.54% and 50.82%, respectively in the control group, compared with 25.41%, 39.61%, 40.55% and 51.57%, respectively in the intervention group; there were no significant differences between intervention group and control group in each stratum. For patients recurred or died within the first 2 years after resection, the median survival of tumor>5 cm and presenting high risk factors for recurrence was 24 months in the intervention group and 12 months in the Control group. Only in this subgroup, the survival curve of the intervention group was significantly higher than that compared to the control group. For patients who remained recurrence free and survived within the first 2 years after resection, there were no significant differences in the recurrence curves between the intervention group and control group in each stratum; while cumulative survival rates in the subgroup of patients with tumor size is less than or equal to 5 cm and presenting low risk factors for recurrence were 93.95%, 91.50% and 88.42% respectively in the control group, compared with 91.70%, 81.32% and 78.19% respectively in the intervention group at 3-, 4- and 5-year after resection (P=0.0062); for other subgroups, there were no significant differences in the survival curves between the intervention group and the control group in each stratum. Cox regression model suggested adjuvant TACE was not an independent risk factor for late recurrence; however, it might have negative effect on survival [hazard ratio (HR)=1.50, P=0.062] for those patients (especially patients with tumor is less than or equal to 5 cm and presenting low risk factors for recurrence). CONCLUSIONS:The value of adjuvant TACE was mainly due to its therapeutic actions on residual tumor or early recurrence. It had no effect on postponing or eliminating late recurrence; moreover, it could be a risk rather than a benefit in patients at low risk for recurrence (especially those with tumor is less than or equal to 5 cm and presenting low risk factors for recurrence).

Clinical Study on Superselective Embolization Treatment to Improve the Quality of Life in Patients with late hepatocarcinoma

Evaluation of the Efficacy for Alternated Treatment on Primary Liver Cancer by Interventional Therapy in Combination with Fractionated Stereotactic Conformal Radiotherapy

Application of superselective interventional embolization treatment on hepatocarcinoma

Clinical Observation of 65 Cases with Hepatocellular Carcinoma Treated by Huqisan and Transeatheter Arterial Chemoembolization

Impact of hepatectomy and postoperative adjuvant transarterial chemoembolization on serum tumor markers and prognosis in intermediate-stage hepatocellular carcinoma

[Effect of Postoperative Adjuvant Transarterial Chemoembolization on Late Recurrence of Hepatocellular Carcinoma after Radical Resection].

Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma

Clinical Efficacy of Transcatheter Arterial Chemoembolization Combined With Percutaneous Microwave Coagulation Therapy for Advanced Hepatocellular Carcinoma

Clinical Study on the Sensitivity Test Guided Hepato-Arterial/portal-vein Chemotherapy in Patients with Unresectable Hepatocellar Carcinoma

Quality of Life of Primary Hepatocellular Carcinoma Patients after Radiofrequency Ablation with or Without Transcatheter Arterial Chemoembolization

Efficacy of traditional herbal medicine versus transcatheter arterial chemoembolization in postsurgical patients with hepatocellular carcinoma: A retrospective study

Efficacy of Hepatic Resectionvstransarterial Chemoembolization for Solitary Huge Hepatocellular Carcinoma

[Effect of Postoperative Transcatheter Arterial Chemoembolization on Hepatocellular Carcinoma Patients with Residual Tumor].

A new thermosensitive embolic agent used for arterial embolization of primary hepatocellular carcinoma:preliminary clinical trial

The Role of Interventional Treatment on Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis

Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone

Effect of chemotherapeutics and embolization on tumor inhibition and liver injury in TACE treatment of hepatic carcinoma

Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial

Surgical Treatment of Primary Hepatoeellular Carcinoma: a 20-Year Clinical Experience in 7566 Patients

Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.

The Study of Curative Effects of Comprehensive Psychological and Behavioral Intervention in Patients with Intermediate and Advanced Liver Cancer